Hamer M E, Wilkinson W E, Clair W K, Page R L, McCarthy E A, Pritchett E L
Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Division of Biometry, Duke University Medical Center, Durham, North Carolina.
J Am Coll Cardiol. 1995 Apr;25(5):984-8. doi: 10.1016/0735-1097(94)00512-o.
This study was performed to determine the incidence of symptomatic, sustained atrial fibrillation in a group of patients with paroxysmal supraventricular tachycardia. The effects of the mechanism of paroxysmal supraventricular tachycardia (atrioventricular [AV] node reentry vs. AV reentry through an accessory pathway) and heart rate during the tachycardia on the occurrence of atrial fibrillation were also assessed.
There is a substantial incidence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia, but the precise incidence and the factors that determine it are unknown.
One hundred sixty-nine patients with paroxysmal supraventricular tachycardia were followed up by regular clinic visits and transtelephonic electrocardiographic monitoring during symptomatic episodes of arrhythmia. The Kaplan-Meier product-limit method was used to estimate the proportion of patients remaining free of atrial fibrillation during the observation period. The Cox proportional hazards model was used to assess the effect of mechanism and heart rate during paroxysmal supraventricular tachycardia on the atrial fibrillation-free period.
Thirty-two (19%) of the 169 patients had an episode of atrial fibrillation during a mean follow-up period of 31 months. The cumulative percent of patients experiencing an episode of atrial fibrillation was 6% within 1 month, 9% within 4 months and 12% within 1 year. The mechanism of paroxysmal supraventricular tachycardia was not associated with the time to occurrence of atrial fibrillation; the hazard ratio corresponding to classification in the AV node reentry group was 0.8 (p > 0.6). The heart rate during paroxysmal supraventricular tachycardia was not associated with the time to occurrence of atrial fibrillation; the hazard ratio associated with an increase in heart rate of 50 beats/min during the tachycardia was 1.15 (p > 0.5).
This study suggests that atrial fibrillation will develop in approximately 12% of patients with paroxysmal supraventricular tachycardia during a 1-year follow-up period. The occurrence of atrial fibrillation is not related to the mechanism or heart rate of the paroxysmal supraventricular tachycardia.
本研究旨在确定一组阵发性室上性心动过速患者中症状性、持续性心房颤动的发生率。同时还评估了阵发性室上性心动过速的机制(房室结折返与通过旁路的房室折返)以及心动过速期间的心率对心房颤动发生的影响。
阵发性室上性心动过速患者中心房颤动的发生率较高,但确切发生率及其决定因素尚不清楚。
对169例阵发性室上性心动过速患者进行定期门诊随访,并在心律失常症状发作期间进行电话心电图监测。采用Kaplan-Meier乘积限界法估计观察期内无房颤患者的比例。采用Cox比例风险模型评估阵发性室上性心动过速期间的机制和心率对无房颤期的影响。
169例患者中,32例(19%)在平均31个月的随访期内发生了心房颤动。发生心房颤动的患者累积百分比在1个月内为6%,4个月内为9%,1年内为12%。阵发性室上性心动过速的机制与心房颤动发生时间无关;房室结折返组分类对应的风险比为0.8(p>0.6)。阵发性室上性心动过速期间的心率与心房颤动发生时间无关;心动过速期间心率增加50次/分钟对应的风险比为1.15(p>0.5)。
本研究表明,在1年的随访期内,约12%的阵发性室上性心动过速患者会发生心房颤动。心房颤动的发生与阵发性室上性心动过速的机制或心率无关。